相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
AMPK and Friends: Central Regulators of β Cell Biology
Jillian L. Rourke et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2018)
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOMEA (R) trial
Naveed Sattar et al.
DIABETOLOGIA (2018)
Emerging roles of SIRT1 in fatty liver diseases
Ren-Bo Ding et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2017)
Resveratrol suppresses lipoprotein-associated phospholipase A2 expression by reducing oxidative stress in macrophages and animal models
Shengnan Sun et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2017)
Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
Seung-Hyun Ko et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2017)
Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice
Atsuo Tahara et al.
ARCHIVES OF PHARMACAL RESEARCH (2016)
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
Yasushi Honda et al.
PLOS ONE (2016)
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
Chikara Komiya et al.
PLOS ONE (2016)
Secondary Metabolites in Ramalina terebrata Detected by UHPLC/ESI/MS/MS and Identification of Parietin as Tau Protein Inhibitor
Alberto Cornejo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
Karen Whalen et al.
CLINICAL THERAPEUTICS (2015)
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient L-amino acid-defined diet in rats
Yuka Hayashizaki-Someya et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up
Mattias Ekstedt et al.
HEPATOLOGY (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients
Stefania Mariani et al.
ENDOCRINE (2015)
Voglibose administration regulates body weight and energy intake in high fat-induced obese mice
Hyun Ju Do et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Obesity and Liver Disease The Epidemic of the Twenty-First Century
Kathleen E. Corey et al.
CLINICS IN LIVER DISEASE (2014)
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
Masanori Yokono et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients With Type 2 Diabetes
Jaime A. Davidson et al.
POSTGRADUATE MEDICINE (2014)
Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
M. Suzuki et al.
NUTRITION & DIABETES (2014)
Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease
Sara Heeboll et al.
WORLD JOURNAL OF HEPATOLOGY (2014)
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Atsuo Tahara et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
Eiji Kurosaki et al.
PHARMACOLOGY & THERAPEUTICS (2013)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ele Ferrannini et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
SREBPs: metabolic integrators in physiology and metabolism
Tae-Il Jeon et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease
Yasar Colak et al.
MEDICAL SCIENCE MONITOR (2011)
Sirtuins regulate key aspects of lipid metabolism
David J. Lomb et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Role of Sirtuin 1 in metabolic regulation
Jose P. Silva et al.
DRUG DISCOVERY TODAY (2010)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway
Guang-Li Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes
Shin-ichiro Imai et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase
Xiuyun Hou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats
Xiang-Qun Deng et al.
LIVER INTERNATIONAL (2007)
Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults
S Jimba et al.
DIABETIC MEDICINE (2005)
SREBP transcription factors:: master regulators of lipid homeostasis
D Eberlé et al.
BIOCHIMIE (2004)
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
AJ Scheen
DRUGS (2003)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Nonalcoholic fatty liver disease - A feature of the metabolic syndrome
G Marchesini et al.
DIABETES (2001)
分享论文
